MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin.
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms MAGELLAN
- Sponsors Bayer HealthCare
- 07 Feb 2013 Results published in the New England Journal of Medicine.
- 03 Jul 2012 Company added in the association field as reported by EudraCT.
- 28 Jul 2011 Results of an analysis of treatment in different patient subgroups presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History